Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Trikafta on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Trikafta (elexacaftor/tezacaftor/ivacaftor) is a CFTR modulator combination approved by the FDA for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene, or another mutation responsive to the combination based on clinical and in vitro data. Trikafta is the US brand of the same active ingredients marketed in the EU and UK as Kaftrio.
Trikafta contains three CFTR modulators that work together: elexacaftor and tezacaftor help the defective CFTR protein fold and traffic correctly to the cell surface, while ivacaftor helps the CFTR protein open more effectively to allow chloride ion transport, addressing the underlying protein defect rather than only managing symptoms.
Trikafta's label has been progressively expanded to cover an increasing range of CFTR variants beyond F508del, based on clinical and laboratory data — a treating CF specialist can confirm current eligibility based on a patient's specific genotype.
For adults and adolescents 12 years and older, the standard regimen is two tablets (elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning and one ivacaftor 150 mg tablet in the evening, approximately 12 hours apart, taken with fat-containing food. Pediatric dosing uses age- and weight-appropriate tablet or granule formulations.
Boxed Warning — Trikafta: Trikafta can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking Trikafta, in both clinical trials and the postmarketing setting.
Liver function tests are recommended at baseline, then monthly for the first six months, then every three months for the next twelve months, and annually thereafter. Trikafta should be interrupted if signs of significant liver injury occur.
Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.
Cases of intracranial hypertension have been reported, and patients should be advised to report symptoms such as headache, vision changes, or nausea.
Mood and behavioral changes have been reported, particularly in adolescents. Non-congenital cataracts have been reported in pediatric patients; ophthalmological exams are recommended before and during treatment in this population.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Trikafta is manufactured and marketed by Vertex Pharmaceuticals Incorporated in the United States. It is not separately marketed in the EU or UK — the identical elexacaftor/tezacaftor/ivacaftor combination is sold there under the brand name Kaftrio. NPP sources Trikafta through authorized US distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating pulmonologist or CF specialist confirming CFTR genotype and eligibility, along with supporting clinical records. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for a rare genetic disease, Trikafta is sourced through authorized US distribution channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Trikafta directly from authorized US pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Trikafta should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Trikafta through NPP's regulated import pathway, with cystic fibrosis specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support cystic fibrosis care coordination and documentation for Trikafta access.
Delhi's major hospitals assist patients with prescription support and documentation for Trikafta.
Bangalore's specialist network offers access coordination for CF patients eligible for Trikafta.
Chennai-based pulmonology specialists coordinate Trikafta access alongside comprehensive CF care.
Hyderabad's care institutions support patients pursuing Trikafta therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Trikafta.
Pune-based specialists assist with prescription support and Trikafta treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Trikafta.
Kochi's specialist units assist patients with the documentation needed for Trikafta access.
Chandigarh's care centers support Trikafta treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Trikafta access process.
Lucknow-based centers assist patients pursuing Trikafta therapy.
Bhubaneswar's institutions support access to Trikafta for eligible patients.
Guwahati's specialists help coordinate Trikafta access for patients across the Northeast.
Patients in other cities across India can also access Trikafta through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
